Canaan Partners Vii Exits Position in Tobira Therapeutics Inc (TBRA)

Tobira Therapeutics Inc (TBRA) : Canaan Partners Vii has sold out all of its stake in Tobira Therapeutics Inc during the most recent quarter, according to the disclosure filed by the company on Jul 6, 2016 with the SEC. The investment management company has sold out 23,806 shares of Tobira Therapeutics Inc which is valued at $289,005.

Other Hedge Funds, Including , Bnp Paribas Arbitrage Sa added TBRA to its portfolio by purchasing 342 company shares during the most recent quarter which is valued at $4,152.

Tobira Therapeutics Inc closed down -0.05 points or -0.41% at $12.09 with 99,150 shares getting traded on Monday. Post opening the session at $12.06, the shares hit an intraday low of $11.99 and an intraday high of $12.58 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

Many Wall Street Analysts have commented on Tobira Therapeutics Inc. Cantor Fitzgerald Initiated Tobira Therapeutics Inc on Jul 6, 2016 to “Buy”, Price Target of the shares are set at $27.H.C. Wainwright Initiated Tobira Therapeutics Inc on Apr 11, 2016 to “Buy”, Price Target of the shares are set at $22.

Tobira Therapeutics Inc. formerly Regado BioSciences Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat liver disease inflammation fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate cenicriviroc (CVC) is an immunomodulator that can be used to treat a number of diseases including non-alcoholic steatohepatitis (NASH) kidney fibrosis HIV-1 and others. The Company is engaged in clinical studies for CVC including the CENTAUR Study an international randomized Phase IIb study of CVC and placebo in patients with NASH and liver fibrosis (NCT02217475). The Company has initiated ORION a Phase IIa Study of Cenicriviroc in obese patients with fatty liver disease. It is also engaged in the Phase I pioglitazone safety combination study. NASH is a type of non-alcoholic fatty liver disease or NAFLD. NAFLD is a liver disease and is associated with obesity and type-2 diabetes.

Leave a Reply

Tobira Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Tobira Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.